Figure 1.

The release of IL-1β by peripheral blood mononuclear cells (PBMCs) in response to inflammasome agonists and sulfasalazine (SSZ). The production of IL-1β by PBMCs from healthy donors (A) and people living with HIV (B), which were treated with inflammasome agonist in vitro (ATP 2 mM for NLRP3; Flagellin 500 ng/mL for NLRC4; poly(dA;dT) 50 μg/mL for AIM2; and MDP 0.1 μg/mL for NLRP1) in the presence of 1 mM SSZ during 4 h of incubation or 2 h for ATP-treated cells, was quantified by ELISA. Statistical comparison between groups was performed using a Wilcoxon matched-pairs signed rank one-tailed test with a confidence level of 95%. (+: presence, −: absence).